Investors like the news that Arrowhead Research (ARWR +19.8%) has received regulatory approval from the Hong Kong Department of Health to begin a phase 2a clinical trial for ARC-520, its RNAi-based drug for the treatment of chronic hepatitis B (HBV) infection.
The phase 2 trial will be conducted at two local hospitals involving two cohorts at two dose levels.
The purpose of the study is to determine the depth and duration of hepatitis B surface antigen ((HBsAg)) reduction after a single IV dose of ARC-520 in combination with entecavir in patients with chronic HBV infection.
Secondary measures are safety, tolerability and pharmacokinetic measures.
All four analysts covering the stock rate it as BUY.
Mutual fund ownership has increased from 11 to 45 over the past 4 quarters.